DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

788 Pedersen ME, Cockcroft JR. What is the role, if any, for betablockers
as initial therapy for uncomplicated hypertension?
Curr Opin Cardiol 2009, 24:325–332.
Perez MI, Musini VM, Wright JM. Pharmacological interventions
for hypertensive emergencies. Cochrane Database of
Systematic Reviews, 2008, Issue 1, Art. No. CD003653.
Pickkers P, Garcha RS, Schachter M, et al. Inhibition of carbonic
anhydrase accounts for the direct vascular effects of
hydrochlorothiazide. Hypertension, 1999, 33:1043–1048.
Pollesello P, Mebazaa A. ATP-dependent potassium channels as
a key target for the treatment of myocardial and vascular dysfunction.
Curr Opin Crit Care, 2004, 10:436–441.
Ramchandra R, Barrett C, Malpas S. Nitric oxide and sympathetic
nerve activity in the control of blood pressure. Clin Exp
Pharmacol Physiol, 2005, 32:440–446.
Regensteiner JG, Hiatt WR. Current medical therapies for
patients with peripheral arterial disease: A critical review. Am
J Med, 2002, 112:49–57.
Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke
statistics 2008 update: A report from the American Heart
Association Statistics Committee and Stroke Statistics
Subcommittee. Circulation, 2008, 117:e25–e146.
Schulz V. Clinical pharmacokinetics of nitroprusside, cyanide,
thiosulphate and thiocyanate. Clin Pharmacokinet, 1984, 9:
239–251.
Schwartz A. Molecular and cellular aspects of calcium channel
antagonism. Am J Cardiol, 1992, 70:6F–8F.
SHEP Cooperative Research Group. Prevention of stroke by
antihypertensive drug treatment in older persons with isolated
systolic hyper-tension. Final results of the Systolic
Hypertension in the Elderly Program (SHEP). JAMA, 1991,
265:3255–3264.
Shih PB, O’Connor DT. Hereditary determinants of human
hypertension: Strategies in the setting of genetic complexity.
Hypertension, 2008, 51:1456–1464.
Sicca DA. Chlorthalidone: Has it always been the best thiazidetype
diuretic? Hypertension, 2006, 47:321–322.
Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy
for hypertension and the risk of primary cardiac arrest.
N Engl J Med, 1994, 330:1852–1857.
Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind
comparison of placebo and active treatment for older patients
with isolated systolic hypertension. The Systolic Hypertension
in Europe (Syst-Eur) Trial Investigators. Lancet, 1997, 350:
757–764.
Staessen JA, Yan L, Tichart T. Oral renin inhibitors. Lancet,
2006, 368:1449–1456.
Stamler JS, Lamas S, Fang FC. Nitrosylation, the prototypic
redox-based signaling mechanism. Cell, 2001, 106:
675–683.
SECTION III
MODULATION OF CARDIOVASCULAR FUNCTION
Stone GW, Ellis SG, Cox DA, et al. The TAXUS-IV Investigators:
A polymer-based, paclitaxel-eluting stent in patients with coronary
artery disease. N Engl J Med, 2004, 350:221–231.
Surks HK, Mochizuki N, Kasai Y, et al. Regulation of myosin
phosphatase by a specific interaction with cGMP-dependent
protein kinase Iα. Science, 1999, 286:1583–1587.
Sydow K, Daiber A, Oelze M, et al. Central role of mitochondrial
aldehyde dehydrogenase and reactive oxygen species in
nitroglycerin tolerance and cross-tolerance. J Clin Invest,
2004, 113:482–489.
Taira N. Differences in cardiovascular profile among calcium
antagonists. Am J Cardiol, 1987, 59:24B–29B.
Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular
pathophysiology and therapeutics. Pharmacol Ther, 2009,
122:216–238.
Tsien RW, Lipscombe D, Madison DV, et al. Multiple types of
neuronal calcium channels and their selective modulation.
Trends Neurosci, 1988, 11:431–438.
van Zwieten PA, Pfaffendorf M. Similarities and differences between
calcium antagonists: Pharmacological aspects. J Hypertens
Suppl, 1993, 11:S3–S11.
Veverka A, Nuzum DS, Jolly JL. Nebivolol: A third-generation
beta-adrenergic blocker. Ann Pharmacother, 2006, 40:
1353–1360.
Waldman SA, Murad F. Cyclic GMP synthesis and function.
Pharmacol Rev, 1987, 39:163–196.
Walsh RA, O’Rourke RA. Direct and indirect effects of calcium
entry blocking agents on isovolumic left ventricular relaxation
in conscious dogs. J Clin Invest, 1985, 75:1426–1434.
Waters D. Proischemic complications of dihydropyridine calcium
channel blockers. Circulation, 1991, 84:2598–2600.
Weber MA. Calcium channel antagonists in the treatment of
hypertension. Am J Cardiovasc Drugs, 2002, 2:415–431.
Wilson SR, Scirica BM, Braunwald E, et al. Efficacy of
ranolazine in patients with chronic angina: Observations
from the randomized, double-blind, placebo-controlled,
MERLIN-TIMI (Metabolic Efficiency with Ranolazine for
Less Ischemia in Non-ST-Segment Elevation Acute Coronary
Syndromes) 36 trial. J Am Coll Cardiol, 2009,
53:1510–1516.
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus
clopidogrel in patients with acute coronary syndromes. N Engl
J Med, 2007, 357:2001–2015.
Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. Unstable
angina pectoris. N Engl J Med, 2000, 342:101–114.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensinconverting
enzyme inhibitor, ramipril, on cardiovascular
events in high-risk patients. The Heart Outcomes Prevention
Evaluation Study Investigators. N Engl J Med, 2000, 342:
145–153.